Navigation Links
James F. Szigethy Named Curemark's Director of New Product Development
Date:9/7/2010

RYE, N.Y., Sept. 7 /PRNewswire/ -- Curemark (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that James F. Szigethy, formerly a consultant for Curemark, has assumed the position of Director of New Product Development.  In his new position, Szigethy will have direct oversight of improving existing products and directing the development of new products.  As Curemark continues to anticipate expansion of its clinical trials program, Szigethy will oversee and coordinate all activities across a variety of Curemark product programs, the company said.

Dr. Joan Fallon, Curemark's Founder and CEO said, "We are very excited  to have James assume this new position.  Curemark has a strong focus on innovation coupled with excellence and James' credentials as an experienced pharmacist and consultant are a tremendous asset to us."

"I am excited to have the opportunity to implement Curemark's strategic vision and this is a truly exciting company to work for," remarked Szigethy.  "Curemark is focused on children with conditions for whom either no treatment or inadequate treatment is available and I am proud to be at the forefront of the development of new products to further our studies and Curemark's mission."

Szigethy's new responsibilities will include formulation development, overseeing Curemark's product production and expansion of its product portfolio. He has been with the company since 2007.

Szigethy graduated from St. John's University in 1994 with a B.A. in Psychology. He attained his B.S. in Pharmacy in 2001 and became a supervising pharmacist for Wal-Mart, where his department was recognized as Wal-Mart's Northeast Region Pharmacy of the Year in 2006.

Curemark currently is conducting Phase III clinical trials for CM-AT, an autism treatment that will be one of the first to address the underlying physiology of autism.  CM-AT is based on Dr. Fallon's breakthrough research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein.  The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function.  The FDA has designated CM-AT as a Fast Track drug.

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thoratec Presentation at Raymond James Conference to Be Webcast
2. Hill-Rom Announces Appointment of James R. Giertz to Board of Directors
3. AMD LASERS Names Dr. James Jesse as Medical Director
4. Dr. James F. Pingpank to Present at Leading Regional Therapies Conference
5. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
6. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
7. Cape Medical Supply Named to Prestigious Inc. 5000 List of Americas Fastest Growing Private Companies for Fourth Year in a Row
8. SAM Medical Products Named to Inc. 5000 List of the Fastest-Growing Private Companies in America
9. MedNet Solutions Named to the Inc. 5000 List of Fastest Growing Companies for the Fourth Consecutive Year
10. BlueDot Medical, Inc. Named to 2010 Inc. 500/5000
11. KPaul Named to the Inc. 500 Fastest Growing Companies List for 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016  Marking its one year anniversary ... ovarian cancer risk test, Color Genomics ... that highly impact the most common hereditary cancers ... Color Test analyzes hereditary cancer risks for breast, ... cancers. The Color Test is physician ordered and ...
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
(Date:4/28/2016)... WARSAW, Ind., April 28, 2016 , Net ... a reported basis over the prior year period, and an ... basis , Diluted EPS for the first quarter were ... period, and $2.00 adjusted, an increase of 29.9% over the ... revenue and adjusted earnings guidance for 2016 Zimmer ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent ... cancer deaths. More than 10,000 people are expected to die of melanoma this year. The ... the one of the most commonly diagnosed cancers in young women. A recent breakthrough in ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston ... and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its ... is a newly patented safety device secured by nasal surgeons onto the floor ...
(Date:4/29/2016)... ... April 29, 2016 , ... Innovations with Ed Begley ... upcoming episode, airing third quarter 2016 via Discovery Channel. Dates and show times ... Dairy Products, located in Greenwood, Wisconsin applies product research and development and continuous ...
(Date:4/29/2016)... ... April 29, 2016 , ... The infertility specialists at ... Sanaz Ghazal, and Dr. Daniel A. Potter -- are proud of the recent release ... Technology (SART). In April, SART published the latest verified data for 375 ...
(Date:4/29/2016)... ... April 29, 2016 , ... International Dehydrated Foods, Inc. (IDF™) will attend ... 4 at the Doubletree by Hilton Hotel in Oak Brook, Illinois. The two-day event ... technologies for protein ingredients. , At the seminar, IDF™ will offer samples of its ...
Breaking Medicine News(10 mins):